Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2020 Nov;31(11):2738-2740.
doi: 10.1681/ASN.2020071096. Epub 2020 Sep 4.

Authors' Reply

Tadao Akizawa  1 , Manabu Iwasaki  2 , Yusuke Yamaguchi  3 , Yoshikatsu Majikawa  4 , Michael Reusch  5
Affiliations
Comment

Authors' Reply

Tadao Akizawa et al. J Am Soc Nephrol. 2020 Nov.
No abstract available

Keywords: chronic kidney disease; erythropoiesis-stimulating agent; hemodialysis; hypoxia-inducible factor; randomized controlled trials.

PubMed Disclaimer

Comment on

References

    1. Akizawa T, Iwasaki M, Yamaguchi Y, Majikawa Y, Reusch M: Phase 3, randomized, double-blind, active-comparator (darbepoetin alfa) study of oral roxadustat in CKD patients with anemia on Hemodialysis in Japan. J Am Soc Nephrol 31: 1628–1639, 2020. - PMC - PubMed
    1. Mercadal L, Metzger M, Haymann JP, Thervet E, Boffa JJ, Flamant M; NephroTest Study Group : The relation of hepcidin to iron disorders, inflammation and hemoglobin in chronic kidney disease [published correction appears in PLoS One 10: e0123145, 2015]. PLoS One 9: e99781, 2014. - PMC - PubMed
    1. Chen N, Qian J, Chen J, Yu X, Mei C, Hao C: Phase 2 studies of oral hypoxia-inducible factor prolyl hydroxylase inhibitor FG-4592 for treatment of anemia in China. Nephrol Dial Transplant 32: 1373–1386, 2017. - PMC - PubMed
    1. Provenzano R, Besarab A, Wright S, Dua S, Zeig S, Nguyen P: Roxadustat (FG-4592) versus epoetin alfa for anemia in patients receiving maintenance hemodialysis: A phase 2, randomized, 6- to 19-week, open-label, active-comparator, dose-ranging, safety and exploratory efficacy study. Am J Kidney Dis 67: 912–924, 2016. - PubMed
    1. Chen N, Hao C, Liu BC, Lin H, Wang C, Xing C: Roxadustat treatment for anemia in patients undergoing long-term dialysis. N Engl J Med 381: 1011–1022, 2019. - PubMed